Pretreatment Non-Invasive Biomarkers as Predictors to Estimate Portal Vein Tumor Thrombosis (PVTT) Risk and Long-Term Survival in HBV-Related Hepatocellular Carcinoma Patients Without PVTT

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca a Cancer J Clinicians. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nature Reviews Disease Primers. 2021;7(1):6. doi:10.1038/s41572-020-00240-3
   PubMed Web of Science ®Google Scholar
• Rumgay H, Arnold M, Ferlay J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022;77(6):1598–1606. doi:10.1016/j.jhep.2022.08.021
   PubMed Web of Science ®Google Scholar
• Lin J, Zhang H, Yu H, et al. Epidemiological characteristics of primary liver cancer in mainland china from 2003 to 2020: a representative multicenter study. Front Oncol. 2022;12:906778. doi:10.3389/fonc.2022.906778
   PubMed Web of Science ®Google Scholar
• Cui F, Blach S, Manzengo Mingiedi C, et al. Global reporting of progress towards elimination of hepatitis B and hepatitis C. Lancet Gastroenterol Hepatol. 2023;8(4):332–342. doi:10.1016/S2468-1253(22)00386-7
   PubMed Web of Science ®Google Scholar
• Hou JL, Zhao W, Lee C, et al. Outcomes of long-term treatment of chronic HBV infection with entecavir or other agents from a randomized trial in 24 countries. Clin Gastroenterol Hepatol. 2020;18(2):457–467.e421. doi:10.1016/j.cgh.2019.07.010
   PubMed Web of Science ®Google Scholar
• Lu J, Zhang XP, Zhong BY, et al. Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west. Lancet Gastroenterol Hepatol. 2019;4(9):721–730. doi:10.1016/S2468-1253(19)30178-5
   PubMed Web of Science ®Google Scholar
• Liu PH, Huo TI, Miksad RA. Hepatocellular carcinoma with portal vein tumor involvement: best management strategies. Semin Liver Disease. 2018;38(3):242–251. doi:10.1055/s-0038-1666805
   PubMed Web of Science ®Google Scholar
• Wang JC, Xia AL, Xu Y, Lu XJ. Comprehensive treatments for hepatocellular carcinoma with portal vein tumor thrombosis. J Cell Physiol. 2019;234(2):1062–1070. doi:10.1002/jcp.27324
   PubMed Web of Science ®Google Scholar
• Wei X, Li N, Li S, et al. Hepatitis B virus infection and active replication promote the formation of vascular invasion in hepatocellular carcinoma. BMC Cancer. 2017;17(1):304. doi:10.1186/s12885-017-3293-6
   PubMed Web of Science ®Google Scholar
• Zhong JH, Ke Y, Gong WF, et al. Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma. Ann Surg. 2014;260(2):329–340. doi:10.1097/SLA.0000000000000236
   PubMed Web of Science ®Google Scholar
• Zhaohui Z, Shunli S, Bin C, et al. Hepatic resection provides survival benefit for selected intermediate-stage (BCLC-B) hepatocellular carcinoma patients. Cancer Res Treat. 2019;51(1):65–72. doi:10.4143/crt.2018.038
   PubMed Web of Science ®Google Scholar
• Chen ZH, Zhang XP, Cai XR, et al. The predictive value of albumin-to-alkaline phosphatase ratio for overall survival of hepatocellular carcinoma patients treated with trans-catheter arterial chemoembolization therapy. J Cancer. 2018;9(19):3467–3478. doi:10.7150/jca.26120
   PubMed Web of Science ®Google Scholar
• Li Q, Lyu Z, Wang L, Li F, Yang Z, Ren W. Albumin-to-alkaline phosphatase ratio associates with good prognosis of hepatitis B virus-positive HCC patients. Onco Targets Ther. 2020;13:2377–2384. doi:10.2147/OTT.S242034
   PubMed Web of Science ®Google Scholar
• Zhang LX, Lv Y, Xu AM, Wang HZ. The prognostic significance of serum gamma-glutamyltransferase levels and AST/ALT in primary hepatic carcinoma. BMC Cancer. 2019;19(1):841. doi:10.1186/s12885-019-6011-8
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang X. Prognostic value of aspartate aminotransferase to platelet ratio index as a noninvasive biomarker in patients with hepatocellular carcinoma: a meta-analysis. Cancer Manage Res. 2018;10:3023–3032. doi:10.2147/CMAR.S174095
   PubMed Web of Science ®Google Scholar
• Kuo YH, Huang TH, Yen YH, et al. Nomogram to predict the long-term overall survival of early-stage hepatocellular carcinoma after radiofrequency ablation. Cancers. 2023;15(12). doi:10.3390/cancers15123156
   Web of Science ®Google Scholar
• Toyoda H, Kumada T, Tada T, Kaneoka Y, Maeda A. A laboratory marker, FIB-4 index, as a predictor for long-term outcomes of hepatocellular carcinoma patients after curative hepatic resection. Surgery. 2015;157(4):699–707. doi:10.1016/j.surg.2014.10.022
   PubMed Web of Science ®Google Scholar
• Berardi G, Morise Z, Sposito C, et al. Development of a nomogram to predict outcome after liver resection for hepatocellular carcinoma in Child-Pugh B cirrhosis. J Hepatol. 2020;72(1):75–84. doi:10.1016/j.jhep.2019.08.032
   PubMed Web of Science ®Google Scholar
• Serenari M, Han KH, Ravaioli F, et al. A nomogram based on liver stiffness predicts postoperative complications in patients with hepatocellular carcinoma. J Hepatol. 2020;73(4):855–862. doi:10.1016/j.jhep.2020.04.032
   PubMed Web of Science ®Google Scholar
• Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-The ALBI grade. J Clin Oncol. 2015;33(6):550–558. doi:10.1200/JCO.2014.57.9151
   PubMed Web of Science ®Google Scholar
• Cheng S, Chen M, Cai J, et al. Chinese expert consensus on multidisciplinary diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus (2018 Edition). Liver Cancer. 2020;9(1):28–40. doi:10.1159/000503685
   PubMed Web of Science ®Google Scholar
• Park JW, Chen M, Colombo M, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Internat. 2015;35(9):2155–2166. doi:10.1111/liv.12818
   PubMed Web of Science ®Google Scholar
• Guarino M, Cucchetti A, Pontillo G, et al. Pattern of macrovascular invasion in hepatocellular carcinoma. Eur J Clin Invest. 2021;51(7):e13542. doi:10.1111/eci.13542
   PubMed Web of Science ®Google Scholar
• Tortora R, Farella N, Morisco F, et al. Development of a risk score to predict portal vein tumor thrombosis in patients with hepatocellular carcinoma. Eur J Gastroenterol Hepatol. 2023;35(7):734–741. doi:10.1097/MEG.0000000000002549
   PubMed Web of Science ®Google Scholar
• Yu MW, Chang HC, Chang SC, et al. Role of reproductive factors in hepatocellular carcinoma: impact on hepatitis B- and C-related risk. Hepatology. 2003;38(6):1393–1400. doi:10.1016/j.hep.2003.09.041
   PubMed Web of Science ®Google Scholar
• Manieri E, Herrera-Melle L, Mora A, et al. Adiponectin accounts for gender differences in hepatocellular carcinoma incidence. J Exp Med. 2019;216(5):1108–1119. doi:10.1084/jem.20181288
   PubMed Web of Science ®Google Scholar
• Triozzi PL, Stirling ER, Song Q, et al. Circulating immune bioenergetic, metabolic, and genetic signatures predict melanoma patients’ response to Anti-PD-1 immune checkpoint blockade. Clin Can Res. 2022;28(6):1192–1202. doi:10.1158/1078-0432.CCR-21-3114
   PubMed Web of Science ®Google Scholar
• Lu Z, Priya Rajan SA, Song Q, et al. 3D scaffold-free microlivers with drug metabolic function generated by lineage-reprogrammed hepatocytes from human fibroblasts. Biomaterials. 2021;269:120668. doi:10.1016/j.biomaterials.2021.120668
   PubMed Web of Science ®Google Scholar
• Zhang DY, Friedman SL. Fibrosis-dependent mechanisms of hepatocarcinogenesis. Hepatology. 2012;56(2):769–775. doi:10.1002/hep.25670
   PubMed Web of Science ®Google Scholar
• Hiraoka A, Kumada T, Michitaka K, Kudo M. Newly proposed ALBI Grade and ALBI-T score as tools for assessment of hepatic function and prognosis in hepatocellular carcinoma patients. Liver Cancer. 2019;8(5):312–325. doi:10.1159/000494844
   PubMed Web of Science ®Google Scholar
• Pinato DJ, Sharma R, Allara E, et al. The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma. J Hepatol. 2017;66(2):338–346. doi:10.1016/j.jhep.2016.09.008
   PubMed Web of Science ®Google Scholar
• Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029–1033. doi:10.1126/science.1160809
   PubMed Web of Science ®Google Scholar
• Greenhouse WV, Lehninger AL. Occurrence of the malate-aspartate shuttle in various tumor types. Cancer Res. 1976;36(4):1392–1396.
   PubMed Web of Science ®Google Scholar
• Wu J, Chen L, Wang Y, Tan W, Huang Z. Prognostic value of aspartate transaminase to alanine transaminase (De Ritis) ratio in solid tumors: a pooled analysis of 9400 patients. Onco Targets Ther. 2019;12:5201–5213. doi:10.2147/OTT.S204403
   PubMed Web of Science ®Google Scholar
• Franco AT, Corken A, Ware J. Platelets at the interface of thrombosis, inflammation, and cancer. Blood. 2015;126(5):582–588. doi:10.1182/blood-2014-08-531582
   PubMed Web of Science ®Google Scholar
• Schlesinger M. Role of platelets and platelet receptors in cancer metastasis. J Hematol Oncol. 2018;11(1):125. doi:10.1186/s13045-018-0669-2
   PubMed Web of Science ®Google Scholar
• Singal AG, Llovet JM, Yarchoan M, et al. AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023;2023:1.
   Google Scholar
• Ndow G, Vo-Quang E, Shimakawa Y, et al. Clinical characteristics and outcomes of patients with cirrhosis and hepatocellular carcinoma in The Gambia, West Africa: a prospective cohort study. Lancet Glob Health. 2023;11(9):e1383–e1392. doi:10.1016/S2214-109X(23)00263-2
   PubMed Web of Science ®Google Scholar
• Xu XS, Chen W, Miao RC, et al. Survival analysis of hepatocellular carcinoma: a comparison between young patients and aged patients. Chinese Med J. 2015;128(13):1793–1800. doi:10.4103/0366-6999.159356
   PubMed Web of Science ®Google Scholar
• Hsu CY, Liu PH, Ho SY, et al. Metastasis in patients with hepatocellular carcinoma: prevalence, determinants, prognostic impact and ability to improve the Barcelona clinic liver cancer system. Liver Internat. 2018;38(10):1803–1811. doi:10.1111/liv.13748
   PubMed Web of Science ®Google Scholar
• Pawlik TM, Delman KA, Vauthey JN, et al. Tumor size predicts vascular invasion and histologic grade: implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transplant. 2005;11(9):1086–1092. doi:10.1002/lt.20472
   PubMed Web of Science ®Google Scholar
• Mizejewski GJ. Does alpha-fetoprotein contribute to the mortality and morbidity of human hepatocellular carcinoma? A commentary. J Hepatocell Carcinoma. 2016;3:37–40. doi:10.2147/JHC.S114198
   PubMed Web of Science ®Google Scholar
• Farinati F, Marino D, De Giorgio M, et al. Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither? Am J Gastroenterol. 2006;101(3):524–532. doi:10.1111/j.1572-0241.2006.00443.x
   PubMed Web of Science ®Google Scholar
• Giannini EG, Marenco S, Borgonovo G, et al. Alpha-fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis. Hepatology. 2012;56(4):1371–1379. doi:10.1002/hep.25814
   PubMed Web of Science ®Google Scholar
• Hu Z, Sun X, Mei J, et al. Antiviral treatments eliminate the adverse impacts of high baseline HBV loads on the survival of HBV-Related HCC patients. J Hepatocell Carcinoma. 2022;9:315–325. doi:10.2147/JHC.S363123
   PubMed Web of Science ®Google Scholar